Independent Study finds, specific Amino Acids and Anti-Oxidants, provide targeted support for those who suffer from IOP and Glaucoma..
Antioxidants Protect Trabecular Meshwork in Glaucoma – Mitochondrial Dysfunction & Antioxidants: Yuan He, et al. Mitochondrial Complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: Protection by antioxidants, Invest Ophthalmol Vis Sci 49:1447-58, 2008.
Note: The independent study below finds that the antioxidants vitamin E and N-acetyl cysteine (NAC) may reduce the progression of glaucoma. Additionally noted is that effectively reducing or even reversing oxidation may facilitate a healing response in the trabecular meshwork or outflow pathway in the eyes of glaucoma patients, a key suspect in the progression of POAG is local oxidative stress. Oxidative free radicals and reactive oxygen species (ROS) are reported to trigger degeneration in the trabecular meshwork, subsequently leading to increases in IOP and glaucoma.
“Reversing oxidation may facilitate a healing response in the trabecular meshwork or outflow pathway in the eyes of glaucoma patients..”
Can-C Plus™ (2 capsules daily) – by Innovative Vision Products – enhances free radical protection and reduces the oxidative environment inside the eye.
|N-Acetyl Cysteine (a glutithione precurser)||600 mg|
|Vitamin E||150 IU|
|Zinc picolinate||15 mg|
The finding of a protective effect of vitamin E and N-acetyl cysteine (a key component of glutathione) adds to the growing evidence that antioxidants are beneficial in POAG.” Dr. Yuan He
1% N-acetylcarnosine Can-C eye drops™ – Aproved by Innovative Vision Products
- Powerful Anti-glycation properties reverse the cross linking of proteins in the eye.
- Effectively Protects against oxidative stress both in the lipid phase of cellular membranes and in the aqueous environment.
- Efficiently Reverses the free-radical induced oxidation process of degeneration.
Antioxidants Protect Trabecular Meshwork in Glaucoma
Mitochondrial Dysfunction & Antioxidants – Yuan He, et al. Mitochondrial Complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: Protection by antioxidants, Invest Ophthalmol Vis Sci 49:1447-58, 2008.
Primary open angle glaucoma (POAG) is generally associated with elevations in intraocular pressure (IOP) caused by abnormal resistance of aqueous outflow through the trabecular meshwork, a specialized tissue lining the eye’s outflow pathway. A key suspect in the progression of POAG is local oxidative stress. Oxidative free radicals and reactive oxygen species (ROS) are reported to trigger degeneration in the trabecular meshwork, subsequently leading to increases in IOP and glaucoma. There is mounting evidence that ROS play a fundamental role in reducing local antioxidant activities in the region of the trabecular meshwork. The mitochondria are the main source of cellular ROS and adenosine triphosphate (ATP), and are key regulators of mechanisms controlling cell survival and death. A spectrum of mitochondrial abnormalities in patients with POAG has recently been reported.
The authors of a newly published paper (1), now provide evidence that mitochondrial dysfunction is a possible mechanism for the loss of trabecular meshwork cells in POAG. They also report that the antioxidants vitamin E and n-acetyl cysteine (NAC), as well as mitochondrial permeability transition (MPT) inhibitors, can reduce the progression of this condition.
Study Design and Methods Trabecular meshwork from patients with POAG and age-matched subjects without disease were obtained by standard surgical trabeculectomy. Primary cultures of trabecular meshwork were treated with 3 different respiratory chain inhibitors specific for Complex I, II and III. The protective effect of vitamin E, N-acetylcysteine and cyclosporine A was examined by adding these antioxidants or the MPT inhibitor to the cells 30 minutes before treatment with the respiratory chain inhibitors. Mitochondrial function was determined by changes in mitochondrial membrane potential and ATP production with fluorescent probes and a luciferin/luciferase-based ATP assay, respectively. ROS levels were determined by H2-DCF-DA, and cell death was measured by lactate dehydrogenase activity.
Results The trabecular meshwork cells of patients with POAG exhibited senescence and degeneration compared with those of the controls. There was spontaneous generation of ROS, decreased mitochondrial membrane potential, decreased ATP production, and loss of cell viability in primary cell cultures of patients with POAG compared with those of control subjects. ROS generation was associated with dysfunction at the level of mitochondrial complex I.
It was also determined that Vitamin E, N-Acetylcystein and the MPT inhibitor cyclosporine A, protected POAG trabecular meshwork cells from cytotoxicity by attenuating ROS production and cytochrome c release from the mitochondria and by inhibiting the mitochondrial permeability transition opening.
Comments: Taken together, the results of this research support the hypothesis that a defect in mitochondrial complex I, contribute to progressive loss of trabecular meshwork cells in patients with POAG by promoting excessive mitochondrial ROS production. The finding of a protective effect of vitamin E and NAC (a key component of glutathione) adds to the growing evidence that antioxidants are beneficial in POAG and are worthy of further investigation.
(A) Reduction of ROS production in GTM cells by antioxidants Vit E and NAC. Treatment with antioxidants vitamin E (Vit E; 200 µM) or N-acetylcysteine (NAC; 10 mM) induced a decrease in ROS production in GTM cells. Pre-treatment with Vit E or NAC for 30 minutes also significantly reduced ROT-induced ROS production in GTM cells. Data are expressed as a fold change in fluorescence levels of GTM to NTM. Results are expressed as the mean SE of six separate experiments performed in triplicate. *Significant differences from untreated control at P = 0.05. Reference
- Yuan He, et al. Mitochondrial Complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: Protection by antioxidants, Invest Ophthalmol Vis Sci 49:1447-58, 2008.
“Melatonin has a promising newrole in the treatment and management of Glaucoma..”
Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP. Vis Neurosci. 2006 Nov-Dec;23(6):853-62. Review: Department of Optometry and Vision Sciences, Buskerud University College, Kongsberg, Norway. “Melatonin cytoprotective properties may have practical implications in the treatment of ocular diseases, likeglaucoma and age-related macular degeneration”
Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, Rosenstein RE. Exp Eye Res. 2007 Jun;84(6):1021-30. Epub 2006 Dec 14. Review. Department of Optometry and Vision Sciences, Buskerud University College, Kongsberg, 3601 Ko, Norway. “Melatonin, being an efficient antioxidant with antinitridergic properties, has a promising role in the treatment and management of glaucoma.”
Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan DX, Reiter RJ. J Pineal Res. 2006 Mar;40(2):101-9. Review. Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA. email@example.com “Current evidence suggests that melatonin may act as a protective agent in ocular conditions such as photo-keratitis, cataract, glaucoma and retinopathy.”
“Supplementation with melatonin, a potent antioxidant, in especially the aged population should be considered as a prophylaxis to preserve visual functions.”
The use of Melatonin in the treatment of eye disease was the subject of the Stromboli conferences in Italy 3 years ago. This study was published by the NY Academy of Sciences. Please do not fail to recommend Dr. Walter Pierpaoli’s bonded Melatonin formula, as there is virtually no downside and tremendous benefits of for the correct Melatonin application which are well documented and far reaching. “ Gary F. Gordon MD,DO,MD(H) – President, Gordon Research Institute
Dr. Walter Pierpaoli’s Bonded Melatonin Formula ARMeD™ contains a unique melatonin, from organic pharmaceutical grade, plant based ingredients, bonded with selenium and zinc. Additionally, Dr. Pierpaoli and his colleagues included critical excipients which work with the melatonin in regulating fundamental immunological hormone functions to a much greater degree. Please note that ARMeD™ is quite distinct from the sublingual and time-released versions of melatonin as they have a preset time of release which does not mirror the body’s natural circadian rhythm. ARMeD™ actually mimics nature by improving upon the body’s own natural night peak release of melatonin and the results of this superior action speak for themselves..
A two month supply! (60 caps) Only $43.49